Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market
Executive Summary
With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.
You may also be interested in...
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Remain Skeptical
Synta provided one-year follow-up data for its Phase IIb/III trial testing ganetespib in NSCLC and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.
Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical
Synta provided one-year follow up data for its Phase IIb/III trial testing ganetespib in NSCLC, and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.
Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year
The U.S. biotech, which went public last year, plans to file EC145 and a companion diagnostic for conditional approval in Europe in platinum-resistant ovarian cancer in the third quarter, based on findings from four Phase I and Phase II trials.